PO-332 Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E-inhibition in melanoma
Batool Shannan(Vrije Universiteit Brussel), Alexander Roesch(Essen University Hospital), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Johann Matschke(Essen University Hospital), Diana Klein(Institut für Medizinische Informatik, Biometrie und Epidemiologie), Heike Chauvistré(Essen University Hospital), Felix C. E. Vogel(German Cancer Research Center)
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k